WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Sana Biotechnology | June 23, 2020
A startup company developing in vivo and ex vivo cell therapies has raised a significant chunk of funding for its initial financing from life science and technology venture capital as well as pension plans and others.Seattle-based Sana Biotechnology said Tuesday that it had raised more than $700 million from a wide range of investors, including ARCH Venture Partners, Flagship Pioneering, the Canada Pension Plan Investment Board, Baillie Gifford, F-Prime Capital, the Alaska Permanent Fund, ...
Helix | March 09, 2022
HealthPartners and leading genomics company, Helix, are launching myGenetics, a population genomics program that will provide important health information to families across Minnesota and surrounding states.
The myGenetics program hopes to enroll more than 100,000 participants over four years. Genomic data generated will be integrated with patient health records and shared during their personal clinical care. Through the partnership, HealthPartners will be able to identify risk ea...
Cell and Gene Therapy
Cellistic and Ncardia | September 20, 2022
Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced today a transaction whereby Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice grade cell therapy manufacturing capability, including the existing facility and all related personnel.
Under the terms of an asset ...
QIAGEN and Neuron23™ | September 15, 2022
QIAGEN and Neuron23 Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, announced the signing of an agreement to develop a companion diagnostic for Neuron23’s brain penetrant leucine-rich repeat kinase inhibitor for Parkinson’s disease.
Under the new Master Collaboration Agreement, QIAGEN will develop and validate a clinical trial assay that will detect a combination of bi...
Medical, Industry Outlook
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE